Medicis Pharmaceutical to Present at Deutsche Banc Alex. Brown Health Care Conference

SCOTTSDALE, Ariz.--May 4, 2001--Medicis Pharmaceutical Corporation (NYSE:MRX) today announced that a live webcast of its presentation scheduled for Tuesday, May 8, 2001, at 2:30 p.m. E.D.T. (11:30 a.m. P.D.T.), may be accessed via the Internet.

Medicis is scheduled to present at the Deutsche Banc Alex. Brown 2001 Health Care Conference at the Marriott Waterfront Hotel in Baltimore, Maryland.

The webcast will be available via a link on the Medicis corporate web site at http://www.medicis.com/ir/index.html. This link will allow any visitor to the web site to access the Medicis presentation. An archive of the webcast will be available on the Medicis corporate web site at the same URL address for 30 days following the conference.

Medicis is the leading independent pharmaceutical company in the United States focusing primarily on the treatment of dermatological conditions. Medicis develops and markets leading products for major segments within dermatology including acne, fungal infections, psoriasis, eczema, rosacea, seborrheic dermatitis, head lice and cosmesis (improvement in the texture and appearance of skin). Primary products include the prescription brands DYNACIN(R) (minocycline HCl), TRIAZ(R) (benzoyl peroxide), LUSTRA(R) (hydroquinone), LOPROX(R) (ciclopirox), OVIDE(R) (malathion), PLEXION(TM) (sodium sulfacetamide/sulfur), LIDEX(R) (fluocinonide), SYNALAR(R) (fluocinolone acetonide), TOPICORT(R) (desoximetasone), NOVACET(R) (sodium sulfacetamide/sulfur) and A/T/S(R) (erythromycin); the over-the-counter brand ESOTERICA(R); and BUPHENYL(TM) (sodium phenylbutyrate), a prescription product indicated in the treatment of Urea Cycle Disorder.

Except for historical information, this news release contains certain forward-looking statements that involve risks and uncertainties which may cause actual results to differ materially from the statements made, including the Company's dependence on sales of key products, uncertainty of future financial results and fluctuations in operating results, dependence on the Company's acquisition strategy, new product introductions and other risks described from time to time in the Company's SEC filings. These forward-looking statements represent the judgment of the Company, as of the date of this release, and Medicis disclaims any intent or obligation to update these forward-looking statements.

NOTE: Full prescribing information for any Medicis prescription product is available by contacting the Company.

Contacts:
Medicis Pharmaceutical Corporation, Scottsdale
Libby Ivy, 602/808-3854
www.medicis.com